Samsung Biologics (KRX:207940) will invest ₩15.4 trillion over eight years to expand manufacturing and develop new modalities beyond antibody drugs, the company said Wednesday. The planned capex signals readiness to commit upstream capacity ahead of customer demand, a model Seoul-based contract makers have pursued to stay ahead of global rivals.
The investment spans subcutaneous formulations, peptides and antibody-drug conjugates alongside traditional monoclonal antibody production. Samsung Biologics is funding the Daejeon plant expansion through a ₩3.0 trillion rights offering approved 28 August, with the first tranche closing 14 September.
The company's market capitalisation was ₩68.4 trillion at Thursday's close. First-half operating margin stood at 44.4%, the highest since its 2026 spin-off from Samsung Bioepis, with gross margins at 53% against cost of revenue of ₩1.2 trillion on revenue of ₩2.6 trillion.
A second CDMO player, Lonza, announced a ₩1.2 trillion Swiss plant overhaul in May 2026. Industry-wide capex rose across 2025 and 2026 as clients front-loaded capacity before supply tightened further.
kstock reads DART every morning and writes up what moved — the contract, the buyback, the number that does not add up. The daily post and a Saturday roundup, by email.
| Symbol | Last Price |
|---|---|
| 207940Samsung Biologics Co., Ltd. | ₩1,447,000 -2.0% |